MX357542B - Nepicastat para usarse en el tratamiento de dependencia. - Google Patents

Nepicastat para usarse en el tratamiento de dependencia.

Info

Publication number
MX357542B
MX357542B MX2015009454A MX2015009454A MX357542B MX 357542 B MX357542 B MX 357542B MX 2015009454 A MX2015009454 A MX 2015009454A MX 2015009454 A MX2015009454 A MX 2015009454A MX 357542 B MX357542 B MX 357542B
Authority
MX
Mexico
Prior art keywords
methods
dependence
patients
treat
treating dependence
Prior art date
Application number
MX2015009454A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Lesley Pickford
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of MX357542B publication Critical patent/MX357542B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2015009454A 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia. MX357542B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93532307P 2007-08-06 2007-08-06
US95655507P 2007-08-17 2007-08-17
US96059107P 2007-10-04 2007-10-04
PCT/US2008/072357 WO2009021055A1 (en) 2007-08-06 2008-08-06 Methods for treating dependence

Publications (1)

Publication Number Publication Date
MX357542B true MX357542B (es) 2018-07-13

Family

ID=40341713

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015009454A MX357542B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia.
MX2018008628A MX391921B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia
MX2010001390A MX2010001390A (es) 2007-08-06 2008-08-06 Métodos para el tratamiento de dependencia.
MX2022001510A MX2022001510A (es) 2007-08-06 2010-02-04 Nepicastat para usarse en el tratamiento de dependencia.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2018008628A MX391921B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia
MX2010001390A MX2010001390A (es) 2007-08-06 2008-08-06 Métodos para el tratamiento de dependencia.
MX2022001510A MX2022001510A (es) 2007-08-06 2010-02-04 Nepicastat para usarse en el tratamiento de dependencia.

Country Status (16)

Country Link
US (3) US20090041800A1 (cg-RX-API-DMAC7.html)
EP (2) EP2182804B1 (cg-RX-API-DMAC7.html)
JP (5) JP2010535801A (cg-RX-API-DMAC7.html)
CN (2) CN101815438A (cg-RX-API-DMAC7.html)
AU (1) AU2008283903B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0815089A2 (cg-RX-API-DMAC7.html)
CA (1) CA2695372C (cg-RX-API-DMAC7.html)
CO (1) CO6260015A2 (cg-RX-API-DMAC7.html)
ES (1) ES2638190T3 (cg-RX-API-DMAC7.html)
IL (1) IL257418A (cg-RX-API-DMAC7.html)
MX (4) MX357542B (cg-RX-API-DMAC7.html)
NZ (1) NZ583192A (cg-RX-API-DMAC7.html)
PH (1) PH12015502210A1 (cg-RX-API-DMAC7.html)
RU (1) RU2491067C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201705968RA (cg-RX-API-DMAC7.html)
WO (1) WO2009021055A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182804B1 (en) 2007-08-06 2017-05-24 Biotie Therapies, Inc. Methods for treating dependence
WO2010124089A2 (en) * 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
US9804149B2 (en) * 2012-10-10 2017-10-31 Bio-Rad Laboratories, Inc. Patient-based results display
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20170235908A1 (en) * 2015-11-15 2017-08-17 Oriah Behaviorial Health, Inc. Systems and Methods for Managing and Treating Substance Abuse Addiction
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CN110996912A (zh) * 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN108066355A (zh) * 2017-12-28 2018-05-25 宁夏恩多芬科技有限公司 Nitrous Oxide作为治疗神经官能症的用途
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2021089872A1 (en) * 2019-11-07 2021-05-14 Small Pharma Ltd Compounds
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
CA3192009A1 (en) * 2020-08-17 2022-02-24 The Research Foundation For Mental Hygiene, Inc. Use of neuromelanin-sensitive mri as a biomarker of dopamine function
WO2022084892A1 (en) * 2020-10-24 2022-04-28 Universitatsspital Basel Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112690771B (zh) * 2020-12-09 2022-05-24 华南理工大学 一种利用线性回归模型的人脸视频心率检测方法
CN117098496A (zh) 2021-03-11 2023-11-21 人类生物科学股份有限公司 用于协调包括生物标志物的成像数据集的系统、装置和方法
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt
CN119487007A (zh) 2022-09-16 2025-02-18 江苏亚虹医药科技股份有限公司 内匹司他酸加成盐的多晶型及其制备方法和用途
WO2024178082A2 (en) * 2023-02-22 2024-08-29 Freedom Biosciences, Inc. Composition of opioid receptor modulator and mdma for use thereof
CN120754106B (zh) * 2025-09-02 2025-12-09 合肥工业大学 化合物sch23390在制备治疗铅中毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500411A (ja) * 1987-10-07 1991-01-31 マトリックス　テクノロジーズ　インコーポレーテッド コカイン中毒の処置および治療薬
US5593367A (en) * 1995-08-18 1997-01-14 Deere & Company Switchable ignition and starter control system
AU2131697A (en) * 1996-02-23 1997-09-10 Pharm-Eco Laboratories, Incorporated Selective D1 dopamine receptor agonists and partial agonists/antagonist
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
PT1374952E (pt) * 2001-01-17 2006-12-29 Hythiam Inc Utilização de flumazenil no desenvolvimento de um fármaco para o tratamento da dependência do alcoól
US20030040015A1 (en) * 2001-03-07 2003-02-27 Kwang-Soo Kim Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
RU2252756C1 (ru) * 2003-12-23 2005-05-27 Хохлов Александр Петрович Препарат против алкоголизма и наркомании, способ получения такого препарата
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
US20090082341A1 (en) * 2007-07-23 2009-03-26 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
CN101951912A (zh) * 2007-07-23 2011-01-19 辛诺西亚治疗公司 创伤后应激障碍的治疗
EP2182804B1 (en) 2007-08-06 2017-05-24 Biotie Therapies, Inc. Methods for treating dependence
US20100243466A1 (en) 2007-11-26 2010-09-30 Bridgestone Corporation Copper-zinc alloy electroplating bath and plating method using the copper-zinc alloy electroplating bath

Also Published As

Publication number Publication date
CA2695372C (en) 2013-01-22
NZ583192A (en) 2012-06-29
JP2014148551A (ja) 2014-08-21
JP2016210798A (ja) 2016-12-15
US20090041800A1 (en) 2009-02-12
MX391921B (es) 2025-03-21
ES2638190T3 (es) 2017-10-19
US20140099336A1 (en) 2014-04-10
AU2008283903A1 (en) 2009-02-12
AU2008283903B2 (en) 2014-01-16
EP2182804A1 (en) 2010-05-12
SG10201705968RA (en) 2017-08-30
RU2491067C2 (ru) 2013-08-27
SG183696A1 (en) 2012-09-27
EP3251670A1 (en) 2017-12-06
WO2009021055A1 (en) 2009-02-12
CO6260015A2 (es) 2011-03-22
JP2010535801A (ja) 2010-11-25
EP2182804A4 (en) 2010-12-22
CA2695372A1 (en) 2009-02-12
EP2182804B1 (en) 2017-05-24
RU2010108249A (ru) 2011-09-20
MX2010001390A (es) 2010-08-02
US10561638B2 (en) 2020-02-18
CN101815438A (zh) 2010-08-25
PH12015502210A1 (en) 2017-04-10
BRPI0815089A2 (pt) 2014-09-30
CN106983747A (zh) 2017-07-28
US20200383951A1 (en) 2020-12-10
IL257418A (en) 2018-04-30
MX2022001510A (es) 2022-08-11
JP2020114883A (ja) 2020-07-30
JP2018154645A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
MX357542B (es) Nepicastat para usarse en el tratamiento de dependencia.
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
MX376937B (es) Metodos para tratar cancer pancreático mediante el uso de terapias de combinacion que comprenden irinotecano liposómico.
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
BRPI0922301A2 (pt) combinações de inibidor de hsp90
BRPI1006608A2 (pt) Composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
WO2010087642A3 (ko) 인슐린 주사위치 안내시트
WO2009111239A3 (en) Pyrrolidine derivatives
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
EP2203169A4 (en) GLYCEMIC INSPECTION, DIABETES TREATMENT, AND OTHER TREATMENTS WITH ACETYLCHOLINESTERASE INHIBITORS
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
MX2012001409A (es) Fragmento de agrina modificado capaz de restaurar la potencia muscular para utilizarse como un medicamento.
BRPI1015216A2 (pt) método de tratar ou prevenir uma condição médica em um indivíduo.
MX2012014163A (es) Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
CO6470793A2 (es) Antagonistas ccr3 arilsulfonamida
BRPI0819195A2 (pt) métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
BRPI0921011A2 (pt) métodos para provocar pelo menos um de um aumento no umedecimento oral e alívio de um sintoma associado com a hipossalivação , e aumento nos níveis de umedecimento oral, e, produto para cuidado oral
AR068585A1 (es) Composiciones para el tratamiento de telas
CL2011002444A1 (es) Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.
UY32346A (es) Método para tratar la degeneración macular
NO20092078L (no) Fremgangsmate for behandling av alkoholmisbruk, adiksjon og avhengighet
WO2014066400A3 (en) Methods for the effective treatment of metastatic cancer